NASDAQ$VRDN
Viridian Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Miragen Therapeutics announced financial results for Q3 2020 and provided corporate updates, including the acquisition of Viridian Therapeutics and a private placement financing.
Miragen Therapeutics reported a net loss of $5.5 million for the third quarter of 2020. The company completed the acquisition of Viridian Therapeutics and closed a private placement financing, resulting in approximately $144 million in cash on hand and an estimated cash runway through 2023.
- Completed acquisition of Viridian Therapeutics, including VRDN-001 for thyroid eye disease (TED) treatment.
- Closed private placement financing with proceeds of approximately $91 million.
- Pro forma cash on hand of approximately $144 million with estimated cash runway through 2023.
- Announced a 1-for-15 reverse stock split effective November 12, 2020.
Headline financials
Revenue & EPS history
Viridian Therapeutics · Revenue · Quarterly
$0
Revenue by segment
Viridian Therapeutics · $98K total across 1 segment · Q1 2023
- Collaboration Revenue - related party$98K—100.0%
Forward guidance
miRagen believes that its current cash and cash equivalents including approximately $91.0 million in gross proceeds from the sale of its Preferred Stock in a private placement and the cash acquired with the Viridian acquisition, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+2.0%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+1.6%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+73.1%
Q2 2022
Best reaction
-23.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +33.5% | +18.2% | +17.9% | |
| Q4 2025 | +1.9% | +1.3% | -5.4% | |
| Q3 2025 | +8.3% | +22.6% | +42.0% | |
| Q1 2025 | +2.6% | +8.2% | +25.8% | |
| Q4 2024 | +1.6% | -0.1% | -5.6% | |
| Q3 2024 | -12.6% | -21.7% | -30.0% | |
| Q2 2024 | -2.5% | -4.5% | -8.5% | |
| Q1 2024 | -8.1% | -5.3% | -19.6% | |
| Q4 2023 | +4.7% | +3.2% | -9.1% | |
| Q3 2023 | +10.6% | +15.4% | +39.8% | |
| Q2 2023 | +8.6% | +10.6% | +5.6% | |
| Q1 2023 | -0.5% | -8.1% | -0.1% | |
| Q4 2022 | -11.0% | -12.4% | -22.8% | |
| Q3 2022 | +11.4% | +9.9% | +36.1% | |
| Q2 2022 | +73.1% | +60.1% | +56.1% | |
| Q1 2022 | +35.1% | +44.3% | +8.6% | |
| Q4 2021 | +2.2% | +1.4% | -5.3% | |
| Q3 2021 | +6.0% | +2.1% | +5.1% | |
| Q2 2021 | -15.5% | -18.4% | -12.4% | |
| Q1 2021 | -4.4% | -9.4% | -12.4% | |
| Q4 2020 | +3.4% | -4.9% | +5.5% | |
| Q3 2020 | -4.4% | -6.9% | +14.9% | |
| Q2 2020 | -4.4% | +1.8% | -21.1% | |
| Q1 2020 | +3.5% | +20.2% | +52.6% | |
| Q4 2019 | -23.7% | -37.1% | -31.0% | |
| Q3 2019 | -3.2% | -19.2% | -21.9% | |
| Q2 2019 | -2.3% | -7.5% | -18.0% | |
| Q1 2019 | -0.4% | -2.5% | -17.4% | |
| Q4 2018 | +6.2% | +11.3% | +15.6% | |
| Q3 2018 | -5.3% | -17.2% | -27.5% | |
| Q2 2018 | -8.0% | -7.5% | -7.5% | |
| Q1 2018 | -0.5% | +2.1% | -2.0% | |
| Q4 2017 | +3.1% | +7.5% | -7.8% | |
| Q3 2017 | -3.1% | -11.2% | +0.3% | |
| Q2 2017 | -12.6% | -13.5% | -17.9% | |
| Q1 2017 | +2.2% | +2.1% | -16.7% | |
| Q4 2016 | +10.9% | +6.4% | +5.9% | |
| Q3 2016 | +7.3% | -10.2% | +57.7% | |
| Q2 2016 | +1.2% | -3.7% | -6.1% | |
| Q1 2016 | -1.6% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -5.0% | — | — | |
| Q2 2015 | -10.6% | — | — | |
| Q1 2015 | -6.8% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | +9.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro